Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
Clinical trial NCT03703596 · UNKNOWN
Trial details
- NCT number
- NCT03703596
- Sponsor
- Sichuan Cancer Hospital and Research Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-16
- Primary completion
- 2019-11-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.